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Abstract
Background: Myeloid cells are an abundant leukocyte in many types of tumors and contribute to immune evasion.
Expression of the enzyme arginase 1 (Arg1) is a defining feature of immunosuppressive myeloid cells and leads to
depletion of L-arginine, a nutrient required for T cell and natural killer (NK) cell proliferation. Here we use CB-1158, a
potent and orally-bioavailable small-molecule inhibitor of arginase, to investigate the role of Arg1 in regulating anti-
tumor immunity.
Methods: CB-1158 was tested for the ability to block myeloid cell-mediated inhibition of T cell proliferation in vitro,
and for tumor growth inhibition in syngeneic mouse models of cancer as a single agent and in combination with
other therapies. Tumors from animals treated with CB-1158 were profiled for changes in immune cell subsets, expression
of immune-related genes, and cytokines. Human tumor tissue microarrays were probed for Arg1 expression by
immunohistochemistry and immunofluorescence. Cancer patient plasma samples were assessed for Arg1 protein and
L-arginine by ELISA and mass spectrometry, respectively.
Results: CB-1158 blocked myeloid cell-mediated suppression of T cell proliferation in vitro and reduced tumor growth
in multiple mouse models of cancer, as a single agent and in combination with checkpoint blockade, adoptive T cell
therapy, adoptive NK cell therapy, and the chemotherapy agent gemcitabine. Profiling of the tumor microenvironment
revealed that CB-1158 increased tumor-infiltrating CD8+ T cells and NK cells, inflammatory cytokines, and expression of
interferon-inducible genes. Patient tumor samples from multiple histologies expressed an abundance of tumor-
infiltrating Arg1+ myeloid cells. Plasma samples from cancer patients exhibited elevated Arg1 and reduced L-
arginine compared to healthy volunteers.
Conclusions: These results demonstrate that Arg1 is a key mediator of immune suppression and that inhibiting Arg1
with CB-1158 shifts the immune landscape toward a pro-inflammatory environment, blunting myeloid cell-mediated
immune evasion and reducing tumor growth. Furthermore, our results suggest that arginase blockade by CB-1158 may
be an effective therapy in multiple types of cancer and combining CB-1158 with standard-of-care chemotherapy or
other immunotherapies may yield improved clinical responses.
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Background
Myeloid cells in the tumor microenvironment
(TME) are associated with poor prognosis across
multiple types of cancer, including lung, colorectal,
and breast [1]. Tumor-infiltrating myeloid cells con-
tribute to an immunosuppressive TME through mul-
tiple mechanisms, constraining anti-tumor immunity
and hindering immunotherapy [2, 3]. Agents that
aim to block myeloid cell-mediated immunosuppres-
sion are currently in pre-clinical and clinical devel-
opment, however there are no approved therapies
specifically directed against tumor-associated mye-
loid cells [4, 5].
The major populations of tumor infiltrating mye-
loid cells include tumor-associated macrophages
(TAMs), myeloid-derived suppressor cells (MDSCs),
and granulocytes [2, 6, 7]. A feature common to all
of these immunosuppressive cells is their expression
of the enzyme arginase 1 (Arg1) [8]. Arg1 catalyzes
hydrolysis of the amino acid L-arginine to produce
urea and L-ornithine, thereby depleting extracellular
L-arginine [9]. T cells are auxotrophic for L-arginine,
requiring the amino acid for the rapid and successive
rounds of proliferation that follow T cell antigen re-
ceptor (TCR)-dependent activation of effector cells
[10–12]. In some inflammatory settings, myeloid-
mediated arginine depletion is essential for suppress-
ing excessive T cell proliferation [13]. Blocking Arg1
activity in the context of cancer could therefore shift
the balance of L-arginine metabolism to favor
lymphocyte proliferation. Indeed, in murine studies,
injection of the arginase inhibitor nor-NOHA or gen-
etic disruption of Arg1 in the myeloid compartment
resulted in reduced tumor growth, indicating that
Arg1 is pro-tumorigenic [14, 15]. Thus, pharmaco-
logical inhibition of Arg1 is a compelling therapeutic
strategy for the treatment of cancer.
Here we describe CB-1158, a potent and orally-
bioavailable small-molecule inhibitor of Arg1. In T cell
co-cultures, CB-1158 reversed myeloid cell-mediated
immunosuppression and restored T cell proliferation. In
murine syngeneic tumor models, CB-1158 shifted the
tumor immune landscape toward a pro-inflammatory
TME, resulting in tumor growth inhibition. CB-1158
augmented the efficacy of other anti-cancer agents,
including gemcitabine, antibodies to immune check-
points, adoptive T cell therapy, and adoptive NK cell
therapy, to inhibit tumor growth. The therapeutic po-
tential of targeting Arg1 was further supported in a
screen of cancer patient samples that revealed an
abundance of Arg1-expressing myeloid cells in tumors
and high amounts of Arg1 in plasma. CB-1158 is cur-




CB-1158 was synthesized at Calithera Biosciences [16]
and dissolved in 100% DMSO for biochemical assays or
in Milli-Q water (Millipore, Billerica, MA) for cell-based
assays and in vivo studies. No endotoxin contamination
of CB-1158 preparations was observed. All other chemi-
cals were purchased from Sigma (St. Louis, MO) unless
indicated otherwise.
Flow cytometry antibodies
The following anti-mouse antibodies were used for flow
cytometry: CD45-V450 (30F11), CD45-BV510 (30F11),
CD45-BV605 (30F11), CD8-BV510 (53–6.7), CD25-
BV421 (PC61), CD25-BV605 (PC61) from BD Biosciences
(San Jose, CA); CD3-PerCP-eFluor710 (17A2), CD45-PE-
Cy7 (30F11), NKp46-eFluor660 (29A1.4), CD11b-PE-Cy7
(M1/70), CD68-PE-Cy7 (FA-11) from eBioscience (Thermo
Fisher Scientific, Waltham, MA); CD3-PE (17A2); CD68-
BV421 (FA-11), CD206-AlexaFluor488 (C068C2), CD11b-
PerCP-Cy5.5 (M1/70), CD11b-BV605 (M1/70) from
BioLegend (San Diego, CA); CD11b-PE (M1/70) from
Stemcell Technologies (Vancouver, Canada); and Arg1-
APC (polyclonal) from R&D Systems (Minneapolis, MN).
The following anti-human antibodies were used for flow cy-
tometry: CD66b-PE (G10F5), CD4-PerCP-Cy5.5 (SK3),
CD8-APC (RPA-T8) from BD Biosciences; and CD15-
eF450 (HI98) from eBioscience.
Recombinant arginase activity assays
Recombinant full-length human Arg1 was purchased from
Enzo Life Sciences (Farmingdale, NY). Recombinant hu-
man arginase 2 (Arg2) comprising amino acids 23–254
was purchased from US Biological (Salem, MA). Activity
assays using 2 nM Arg1 or 4 nM Arg2 were performed in
reaction buffer (137 mM NaCl, 2.7 mM KCl, 8 mM
Na2HPO4, 2 mM KH2PO4, 0.005% Triton X-100, 0.5 mM
DTT, 0.5 mM MgCl2, 0.1 mM CaCl2, and 160 μM or 20
mM L-arginine, pH 7.4) at 37 °C for 30 min with a dose-
titration of CB-1158. Activity was determined by a spec-
trophotometric assay using the QuantiChrom Urea Assay
Kit (BioAssay Systems, Hayward, CA) or by quantification
of the generation of 13C(5)-L-ornithine from 13C(6)-L-ar-
ginine using a SCIEX API4000 mass spectrometer
(Applied Biosystems, Foster City, CA). Urea produced or
13C(5)-L-ornithine peak areas were plotted and fitted to a
four-parameter equation using GraphPad Prism software
(San Diego, CA) to determine IC50 values.
Native arginase activity in cell lysates
Human granulocytes or erythrocytes were purified from
healthy donor peripheral blood using a pan-granulocyte
negative selection kit (Stemcell Technologies) or centri-
fugation on a Ficoll layer, respectively. Frozen human
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hepatocytes were purchased from XenoTech (Kansas
City, KS). Lysates were prepared by microtip sonication
followed with clarification by centrifugation. Plasma
samples from renal cell carcinoma (RCC) patients were
obtained by Ficoll centrifugation of whole blood pur-
chased from Conversant Biologics (Huntsville, AL). Gran-
ulocyte lysate was assayed at 0.094 mg/mL, as determined
by bicinchoninic acid/BCA protein assay (ThermoFisher),
in reaction buffer. Erythrocyte or hepatocyte lysates were
assayed at concentrations empirically determined to con-
sume 10–15% of 13C(6)-L-arginine in 30 min at 37 °C. Ar-
ginase activity was determined in lysates and plasma by
quantification of the generation of 13C(5)-L-ornithine
from 13C(6)-L-arginine in the presence of a dose-titration
of CB-1158.
Native arginase activity in intact cells
Intracellular arginase activity was determined for the
arginase-expressing HepG2 and K-562 cell lines as fol-
lows. HepG2 cells were seeded at 100,000 cells per well
one day prior to treatment with CB-1158. K-562 cells
were seeded at 200,000 cells per well on the day of CB-
1158 treatment. Cells were treated with a dose-titration
of CB-1158 in SILAC RPMI-1640 media (Life Technolo-
gies/Thermo Fisher Scientific) containing 5% heat-
inactivated and dialyzed FBS, antibiotics/anti-mycotic,
10 mM L-arginine, 0.27 mM L-lysine, and 2 mM L-
glutamine. The medium was harvested after 24 h and
urea generated was determined with the QuantiChrom
Urea Assay Kit. Wells containing media without cells
were used as background controls. For assessing the ef-
fect of CB-1158 on Arg1 in primary hepatocytes, frozen
human hepatocytes (XenoTech) were thawed, allowed to
adhere onto collagen-coated wells for 4 h, and then in-
cubated for 48 h in SILAC-RPMI containing 10 mM L-
ornithine, no L-arginine, and a dose-titration of CB-
1158, at which time the media were analyzed for urea.
Nitric oxide (NO) synthase (NOS) activity assays
Activity of 50 μM CB-1158 against 3 NOS isoforms, re-
combinant murine inducible NOS, recombinant bovine
endothelial NOS, and native rat cerebellar neuronal NOS,
was determined at Eurofins/Cerep Panlabs (Taipei, Taiwan)
by either quantitation of radiolabeled L-citrulline or spec-
trophotometric measurement of nitrite.
Cell culture
All cell culture reagents were purchased from Corning
(Corning, NY) unless indicated otherwise. The human
cell lines, HepG2 and K-562, and the murine cell lines,
LLC1 (LLC), B16-F10 (B16), CT26.WT (CT26), and 4T1
were obtained from American Type Culture Collection
(ATCC, Manassas, VA). HepG2, K-562, CT26, and 4T1
were maintained in RPMI-1640 (Corning). B16 was
maintained in DMEM (Corning). LLC was maintained
in DMEM (ATCC). All media were supplemented with
10% fetal bovine serum (FBS), plus penicillin, strepto-
mycin, and amphotericin. Cell lines were grown at 37 °C
in a humidified 5% CO2 atmosphere.
Cytotoxicity assays
Cells were seeded in fully-supplemented RPMI-1640
medium, treated with a dose-titration of CB-1158 in
triplicate wells, and incubated for 72 h. Cytotoxicity was
assayed by the addition of CellTiterGlo reagent accord-
ing to the manufacturer’s instructions (Promega, Madi-
son, WI) followed by fluorescence quantification on a
Molecular Devices plate reader (Sunnyvale, CA).
T cell and NK cell proliferation assays
T cells or NK cells were purified from healthy donor hu-
man blood or from murine splenocytes using a negative
selection kit for the appropriate cell type and species
from Stemcell Technologies. Isolated T cells or NK cells
were loaded with carboxyfluorescein succinimidyl ester
(CFSE, Thermo Fisher) and stimulated for 72–96 h in
complete growth medium containing a minimum of ei-
ther 50 μM L-arginine (NK cells) or 100 μM L-arginine
(T cells). For T cell stimulation, a solution of 10 μg/mL
anti-CD3 (human clones UCHT1 or OKT3; murine
clone 145-2C11) was used to coat the wells of a 96-well
plate and then T cells were stimulated on immobilized
anti-CD3 in the presence of 2 μg/mL soluble anti-CD28
(human clone CD28.2; murine clone 37.51). NK cells
were stimulated with recombinant IL-2. Proliferation
was quantified by analyzing CFSE dilution by flow cy-
tometry (Guava flow cytometer, Millipore, Billerica, MA
or Attune NxT flow cytometer, ThermoFisher).
T cell/myeloid cell co-culture assays
Granulocytes were purified from healthy donor periph-
eral blood using a pan-granulocyte negative selection kit
(Stemcell Technologies) and incubated in SILAC-RPMI
medium containing 10% charcoal-stripped FBS, antibi-
otics/anti-mycotic, 0.27 mM L-lysine, 20 μM MnCl2,
100 μM L-arginine, pH 7.4, and a dose-titration of CB-
1158. Freshly isolated granulocytes were incubated for
48 h at 37 °C, during which time they spontaneously ac-
tivate as determined by increased surface expression of
CD66b and scatter properties. T cells isolated from the
same healthy donor using a pan-T cell isolation kit
(Stemcell Technologies) were loaded with CFSE and
plated with immobilized anti-CD3 and soluble anti-
CD28 in the presence of the aged granulocytes. The cells
were co-cultured at several ratios of granulocytes to
T cells as indicated in the figure or at a fixed ratio of
4 T cells to 1 granulocyte. Co-cultures were incubated
for 3–4 days, at which time the medium was analyzed
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for L-arginine and L-ornithine by mass spectrometry and
T cell proliferation was determined by flow cytometry.
Granulocytic MDSC (G-MDSC) or granulocytes from
cancer patients were isolated from whole blood purchased
from Conversant Biologics. G-MDSCs were purified from
the PBMC layer of a Ficoll gradient by positive selection
for CD66b+ cells. Granulocytes were purified from the
RBC layer of a Ficoll gradient using Hetasep (Stemcell
Technologies). Granulocytes and G-MDSCs were charac-
terized by flow cytometry for CD66b expression. Freshly
isolated G-MDSC or granulocytes were incubated in co-
culture medium containing 100 μM L-arginine for 48 h, at
which time the cells were removed and the G-MDSC- or
granulocyte-conditioned media were used for incubating
healthy donor CFSE-loaded T cells on immobilized anti-
CD3/soluble anti-CD28 for 3–4 days. Cytokines were
quantified in the media from T cell co-culture assays using
the Cytometric Bead Array kit according to the manufac-
turer’s instructions (BD Biosciences).
Murine tumor studies
Female wild-type C57BL/6 and Balb/c mice (5–6 weeks
old) were purchased from Charles River Laboratories
(Hollister, CA). Severe combined immune deficient (SCID,
B6.CB17-PrkdcSCID/SzJ) and Pmel-1 TCR transgenic
(B6.Cg-Thy1a/Cy Tg(TcraTcrb)8Rest/J) mice (5–6 weeks
old) were purchased from The Jackson Laboratory (Bar
Harbor, ME). All mice were housed and treated in accord-
ance with Institutional Animal Care and Use Committee
guidelines. For the 4T1 tumor model, 105 cells were
injected orthotopically into the mammary fat pad; for
all other tumor models, 106 cells were injected sub-
cutaneously (s.c.) in the right flank. For all studies, CB-
1158 was administered by oral gavage twice per day at
100 mg/kg starting on study day 1 (1 day after tumor
implant). Control groups received vehicle (water) twice
daily by gavage. Tumor volume measured by digital
caliper (length × width × width/2) and body weight
were recorded three times per week. Animals were eu-
thanized when tumors necrotized or volumes reached
2000 mm3. For the CT26 model, anti-PD-L1 antibody
(5 mg/kg, clone 10F.9G2, BioXCell, West Lebanon,
NH) was injected intraperitoneally (i.p.) on days 5, 7,
9, 11, 13, and 15. For the 4T1 model, anti-CTLA-4
antibody (5 mg/kg, clone 9H10, BioXCell) was injected
i.p. on days 2, 5, and 8; anti-PD-1 antibody (5 mg/kg,
clone RMP1–14, BioXCell) was injected i.p. on days 3,
6, and 9. 4T1 tumors were harvested on study day 25
into Fekete’s solution and tumor nodules were enu-
merated visually. Gemcitabine (Selleckchem, Houston,
TX) was dosed 50 mg/kg i.p. on days 10 and 16 for the
CT26 model, 60 mg/kg i.p. on days 6 and 10 for the
LLC model, or 30 mg/kg i.p. on day 5 for the 4T1
model [17, 18]. With these regimens, gemcitabine
modestly reduces tumor growth and spares most
tumor-infiltrating immune cells, allowing for the
evaluation of combination activity with CB-1158. For
CD8+ cell depletion, mice were injected i.p. with anti-
CD8 antibody (25 mg/kg, clone 2.43, BioXCell) on days
−1, 0, + 5, and +10. For NK cell depletion, mice were
injected i.p. with anti-NK1.1 antibody (25 mg/kg, clone
PK136, BioXCell) in the LLC and B16 models or with
anti-Asialo GM1 sera (20 μL, Wako Chemicals, Rich-
mond, VA) in the CT26 model, per the same schedule
as anti-CD8.
Conditional Arg1 deleted mice
Arg1 floxed mice were crossed to the Tie2-Cre deleter
strain (The Jackson Laboratory) as previously described
[19]. Experimental mice were generated from crossing
Arg1Flox/Flox; Tie2-Cre+ males with Arg1Flox/Flox; Tie2-Cre
− females, with Cre negative littermates serving as wild-
type controls. Mice were housed and treated in accord-
ance with protocols approved by the Institutional Ani-
mal Care and Use Committee at St. Jude Children’s
Research Hospital. LLC cells (106 per mouse) were
injected s.c. in the flank region. Mice were orally
gavaged with either 100 mg/kg of CB-1158 or an equiva-
lent volume of vehicle control (water) every 12 h for
14 days. Mice were euthanized, and tumors excised and
weights recorded. Myeloid deletion of Arg1 was con-
firmed via western blotting of IL-4-stimulated bone
marrow-derived macrophages for all animals.
Adoptive T cell transfer studies
Activated gp100-specific CD8+ (Pmel-1) T cells were gen-
erated as described in Ya et al. [20]. Briefly, splenocytes
from Pmel-1 TCR transgenic mice were isolated, pulsed
with 1 μM of murine gp10025–33 (Anaspec, Fremont, CA)
and expanded for 1 week in the presence of 60 IU/mL re-
combinant human IL-2 (Peprotech, Rocky Hill, NJ). Cells
were >90% CD8+ Vβ13
+ T cells as determined by flow
cytometry. C57BL/6 mice were inoculated s.c. with B16
tumor cells. CB-1158 was administered by oral gavage
twice per day at 100 mg/kg starting 1 day after tumor
implant. On day 7, lymphopenia was induced by a non-
myeloablative chemotherapy regimen of 250 mg/kg
cyclophosphamide and 50 mg/kg fludarabine adminis-
tered i.p. The chemotherapy regimen was administered
to all groups. On day 9, mice were administered 1 × 106
Pmel-1 T cells intravenously (i.v.). Mice receiving Pmel-
1 T cells also received recombinant human IL-2
(200,000 IU/dose) administered i.p. twice daily for
3 days starting the day of T cell transfer.
Adoptive NK cell transfer studies
Balb/c mice were inoculated i.v. with 105 CT26 cells. On
the same day as tumor inoculation, 106 NK cells (isolated
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from Balb/c spleens the day before injection and incu-
bated with recombinant IL-2 and IL-15 for 18 h) were
transferred to the mice. The injected NK cells were pro-
filed by flow cytometry to be CD25+ and 80–90% pure
with less than 0.4% T cells. Mice were treated with vehicle
or CB-1158 for 14 days and then lungs were harvested
into Fekete’s solution and tumor nodules enumerated
visually.
Tumor dissociation and flow cytometry
Tumor-bearing mice treated with vehicle or CB-1158
(100 mg/kg BID) were sacrificed for flow cytometry ana-
lysis on study day 9 (B16), day 10 (4T1), or day 14 (CT26
and LLC). Excised tumors were placed on ice in RPMI-
1640 medium containing 5% FBS, minced with a razor
blade, and dissociated in RPMI-1640 supplemented with
mouse tumor dissociation enzymes (Miltenyi Biotec, Ber-
gisch Gladbach, Germany) on a GentleMACS Octo Disso-
ciator With Heat (Miltenyi Biotec) according to the
manufacturer’s instructions. Dissociated tumors were
strained through 70 μm nylon mesh, washed with cold
PBS containing 2% FBS, blocked with anti-CD16/CD32
(Fc block antibody, eBioscience), and stained for cell sur-
face antigens. For B16 and 4T1 tumors, washed dissoci-
ated tumor cells were incubated with Dead Cell Removal
MicroBeads (Miltenyi Biotec) and applied to a magnetic
column prior to staining. For intracellular staining, cells
were fixed and permeabilized using buffers purchased
from R&D Systems or eBioscience for cytoplasmic or nu-
clear antigens, respectively. All tumor flow experiments
were acquired on an Attune NxT flow cytometer and ana-
lyzed with FlowJo software version 10 (Ashland, OR),
using fluorescence-minus-one controls for gating and
single-stained OneComp eBeads (eBioscience) to set com-
pensation matrices.
Gene expression analysis
LLC tumors from mice (N = 6 per group) treated with
vehicle or CB-1158 (100 mg/kg twice daily) for 13 days
were collected, placed into neutral buffered formalin
overnight, transferred into 70% ethanol, and shipped to
Core Diagnostics (Hayward, CA) for paraffin embedding.
RNA was extracted for gene expression analysis and
transcripts were quantified by NanoString Technologies
(Seattle, WA).
Cytokine analysis
LLC tumors from mice (N = 5 per group) treated with
vehicle or CB-1158 (200 mg/kg twice daily) for 14 days
were collected and flash frozen in liquid nitrogen.
Tumors were homogenized in 50 mM Tris-HCl buffer
containing 2 mM EDTA, pH 7.4 and protease inhibitors.
The homogenate was centrifuged and the supernatant was
collected and re-frozen. Cytokines in the supernatant were
quantified by Myriad Rules Based Medicine (Austin, TX).
Immunohistochemistry (IHC)
Automated IHC was performed by Indivumed (Hamburg,
Germany) using the Discovery XT staining platform
(Roche Diagnostics/Ventana Medical Systems, Mountain
View, CA) on formalin-fixed and paraffin-embedded
(FFPE) samples and tumor tissue microarrays (TMA). The
rabbit anti-human Arg1 monoclonal antibody clone
EPR6672(B) from Abcam/Epitomics (Burlingame, CA)
was validated using 8 different cases of hepatocellular car-
cinoma (HCC) and one sample of normal liver tissue as
positive control tissue; normal tonsil tissue and isotype
control antibody were used as negative controls. IHC was
performed on 11 different tumor histologies: non-small
cell lung cancer (NSCLC, squamous and adenocarcin-
oma), breast cancer (triple negative and non-triple
negative), gastric adenocarcinoma, colorectal cancer
(CRC), prostate adenocarcinoma, pancreatic cancer,
ovarian cancer, bladder cancer, and RCC. Arg1+ cells
per mm2 were quantified by digital histopathology
(OracleBio, Scotland, UK).
Multiparameter immunofluorescence
Tumor TMAs containing samples from patients with
lung squamous cell carcinoma, CRC, RCC, esophageal
carcinoma, and head and neck cancer were purchased
from US Biomax and US Biolabs (Rockville, MD). Multi-
parameter immunofluorescence using the MultiOmyx
platform for markers including Arg1, CD15, and CD68
was performed and analyzed by GE Clarient/NeoGe-
nomics Laboratories (Aliso Viejo, CA).
Plasma Arg1 and L-arginine
The amount of Arg1 protein in plasma samples was de-
termined by enzyme linked immunosorbent assay
(ELISA, BioVendor, Asheville, NC) in specimens from
healthy volunteers and patients with head and neck can-
cer (N = 5), HCC (N = 3), mesothelioma (N = 3), CRC (N
= 3), T cell prolymphocytic leukemia (N = 2), melanoma
(N = 2), bladder cancer (N = 4), NSCLC (N = 11), small
cell lung cancer (N = 17), undefined lung cancer (N = 6),
acute myeloid leukemia (N = 9), RCC (N = 9), and breast
cancer (N = 2). Plasma L-arginine was determined by
mass spectrometry in samples from patients with meso-
thelioma (N = 3), CRC (N = 3), NSCLC (N = 9), small cell
lung cancer (N = 3), undefined lung cancer (N = 3), head
and neck cancer (N = 3), and T cell prolymphocytic
leukemia (N = 2). All cancer patient samples were pur-
chased from Conversant Biologics.
Steggerda et al. Journal for ImmunoTherapy of Cancer  (2017) 5:101 Page 5 of 18
Results
CB-1158 was tested in biochemical and cellular assays
for the ability to inhibit arginase enzymes from a variety
of sources. CB-1158 inhibited recombinant human Arg1
(IC50 = 86 nM) and the related enzyme Arg2 (IC50 =
296 nM) (Table 1). Arg2 catalyzes an identical chemical
reaction and shares 60% sequence identity with Arg1
and differs in its tissue distribution and subcellular
localization [21]. A second enzyme class that also me-
tabolizes L-arginine and is implicated in inflammation is
NOS, which produces L-citrulline and the biological me-
diator NO [8]. CB-1158 was tested for the ability to in-
hibit the three NOS isoforms, endothelial NOS,
neuronal NOS, and inducible NOS. No inhibition of
NOS enzymes was observed in the presence of 50 μM
CB-1158 (Table 1). These results show CB-1158 is a po-
tent inhibitor of arginase with no activity against NOS.
CB-1158 was next tested for the ability to inhibit na-
tive Arg1 in lysates of human granulocytes, peripheral
blood erythrocytes, and primary hepatocytes [22–24].
We found that CB-1158 inhibited native arginase in ly-
sates with similar potency to that observed for recom-
binant arginases (Table 1). In addition, Arg1 protein and
activity have been reported to be elevated in the plasma
of cancer patients compared to healthy donors [25, 26]
and we observed inhibition of arginase activity by CB-
1158 in plasma isolated from cancer patients (Table 1).
Granulocytic Arg1 is inactive until it is exocytosed
[10, 23, 27], however active Arg1 is localized in the
cytoplasm in other cell types, including liver hepato-
cytes. CB-1158 was next tested for the ability to in-
hibit endogenous arginase in intact cells. CB-1158
exhibited low potency against intracellular arginase in
the hepatocellular carcinoma (HCC) cell line HepG2,
the chronic myelogenous leukemia cell line K-562, and
primary human hepatocytes (Table 2). The low potency of
CB-1158 against arginase in intact cells is likely due to in-
efficient penetration of CB-1158 across the cell mem-
brane. These results show that CB-1158 is a potent and
specific inhibitor of extracellular arginase.
To determine if CB-1158 can restore lymphocyte pro-
liferation in the context of immunosuppressive arginase-
expressing myeloid cells, we first confirmed that lym-
phocytes require exogenous L-arginine to proliferate.
Purified T cells or NK cells were stimulated with anti-
CD3/anti-CD28 or IL-2, respectively, in the presence or
absence of L-arginine in the media. Proliferation of
human and murine T cells (Fig. 1a, left) and NK cells
(Fig. 1a, right) only occurred in media that contained L-
arginine, as expected [10, 11, 28, 29].
To determine if arginase activity is necessary for mye-
loid cell-mediated suppression of T cell proliferation, T
cell proliferation was assayed in co-culture with human
myeloid cells in the presence or absence of CB-1158.
Granulocytes are an abundant myeloid cell recruited
from peripheral blood to sites of wound healing, infec-
tion [30], and the TME [25, 31]. Arg1 is stored in cyto-
plasmic granules and upon activation, which occurs
spontaneously in vitro, granulocytes release active Arg1
into the extracellular milieu [10]. Purified human granu-
locytes from a healthy donor consumed L-arginine from
the media (Fig. 1b). When activated granulocytes were
co-cultured with autologous T cells, T cell proliferation
was inhibited (Fig. 1c). The addition of CB-1158 blocked
depletion of L-arginine from the media (Fig. 1d, left) and
restored T cell proliferation to 90% of the proliferation
observed for T cells without granulocytes (Fig. 1d, right).
These results show that L-arginine depletion by Arg1 is
necessary for granulocyte-mediated suppression of T cell
proliferation in vitro, and that CB-1158 reverses this
immunosuppression.




Recombinant human Arg1 86 (±25)
Recombinant human Arg2 296 (±5)
Recombinant bovine endothelial NOS N/A
Rat cerebellar neuronal NOS N/A
Recombinant murine inducible NOS N/A
Cell lysate assay
Human granulocyte lysate 178 (±28)
Human erythrocyte lysate 116
Human hepatocyte lysate 158 (±23)
Cancer patient plasma 122 (±32)
Mean IC50 values in nanomolar for CB-1158 inhibition of purified recombinant
arginases or native arginases in cell lysates or cancer patient plasma. Standard
deviations are indicated in parentheses. Recombinant Arg1 assays (N = 3) were
performed in duplicate wells in the presence of 160 μM L-arginine. Recombinant
Arg2 assays (N = 2) were performed in triplicate wells with 20 mM L-arginine.
Arginase activity assays using human granulocyte lysate (N = 3), human
erythrocyte lysate (N = 1), human hepatocyte lysate (N = 4), and cancer
patient plasma (N = 5) were performed in duplicate wells with 160 μM L-
arginine. Purified NOS enzyme activity was assayed in the presence 50 μM
CB-1158, which showed no inhibitory activity against the three NOS isoforms
N/A not applicable
Table 2 Potency of CB-1158 on arginase activity in intact cells
Intact cell assay CB-1158, IC50 (μM)
Human HepG2 cell line 32 (±5.6)
Human K562 cell line 139 (±8.8)
Primary Human Hepatocytes 210
Mean IC50 values in micromolar for CB-1158 inhibition of arginase activity in
intact cells. Standard deviations are indicated in parentheses. HepG2 (N = 3)
and K562 (N = 2) cell lines were plated in duplicate wells in the presence of
10 mM L-arginine. For primary human hepatocytes (N = 1), arginase activity
was measured in duplicate wells in the presence of media containing 10 mM
L-ornithine and lacking L-arginine. Arginase activity was measured as production
of urea in the media after 24 h
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We next tested if CB-1158 could block T cell suppres-
sion conferred by myeloid cells derived from cancer pa-
tients. G-MDSC purified from the peripheral blood of a
patient with lung cancer or granulocytes purified from a
head and neck cancer patient were cultured for 48 h and
the conditioned media were then used in T cell prolifera-
tion assays. T cells from healthy donors were used in lieu
of the cancer patient donors’ T cells due to the limited
amount of sample available from individual patients. Can-
cer patient-derived G-MDSCs or granulocytes reduced
the amount of L-arginine in the media, and arginine de-
pletion was blocked by CB-1158 (Fig. 1e and f, left panels).
T cell proliferation was inhibited in the media conditioned
by G-MDSC or granulocytes, and proliferation was re-
stored to 99% or 79%, respectively, of control levels by the
addition of CB-1158 (Fig. 1e and f, right panels). CB-1158
also restored secretion into the media of the T cell inflam-
matory cytokines interferon-γ and granzyme-B (Fig. 1g).
Together these data demonstrate that inhibition of argi-
nase by CB-1158 blocks myeloid cell-mediated immuno-
suppression, rescuing T cell proliferation and cytokine
secretion.
To determine if arginase inhibition by CB-1158 could
be tested for anti-tumor efficacy in mouse models of
cancer, pharmacokinetic and pharmacodynamic studies












Fig. 1 Inhibition of arginase reverses myeloid cell-mediated suppression of in vitro T cell proliferation. a T cells (left) and NK cells (right) require
extracellular L-arginine for proliferation. CFSE-loaded T cells or NK cells were stimulated with anti-CD3/anti-CD28 or IL-2, respectively, in media either
containing or lacking L-arginine. Proliferation was measured after 72 h by flow cytometry. b Isolated human granulocytes deplete L-arginine from the
media, measured after 48 h by LC/MS. c Human peripheral blood T cells are suppressed from anti-CD3/anti-CD28-induced proliferation by co-culture
with granulocytes isolated from the same healthy donor. d left, CB-1158 inhibits the consumption of arginine from the media by granulocytes in a
dose-dependent manner; right, CB-1158 inhibits granulocyte-mediated suppression of T-cell proliferation in a dose-dependent manner. The ratio of
granulocytes to T cells in the co-cultures was 0.25 to 1. e, CB-1158 reverses T cell suppression conferred by granulocytic MDSCs. Media conditioned by
granulocytic-MDSCs purified from a lung cancer patient’s blood inhibited T-cell proliferation and is depleted of L-arginine, and both effects are reversed
in a dose-dependent manner by CB-1158. Left, arginine amounts in the media; right, T-cell proliferation. The ratio of MDSCs conditioning the media to
T cells was 1 to 1. f, Conditioned media from purified granulocytes isolated from a head and neck cancer patient’s blood inhibited T-cell proliferation
and are depleted of L-arginine, and both effects are reversed in a dose-dependent manner by CB-1158. Left, arginine amounts in the media; right,
T-cell proliferation. The ratio of granulocytes conditioning the media to T cells was 0.5 to 1. g, CB-1158 reverses the inhibition of secretion of interferon-γ
and granzyme-B conferred by cancer patient granulocytes. Media from panel (f ) were analyzed by Cytometric Bead Array
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single dose of CB-1158 or BID dosing for 5 days, dose-
dependent exposure of CB-1158 was observed in both
plasma and tumors (Fig. 2a and b). Oral dosing of CB-
1158 in tumor-bearing mice also raised the amount of L-
arginine in plasma and tumors, indicating an on-target
pharmacodynamic effect of CB-1158 (Figs. 2a and b).
Importantly, CB-1158 was well-tolerated at doses of
100 mg/kg twice daily for 23 days, with no significant clin-
ical observations or impact on body weight (Fig. 2c).
CB-1158 was tested in multiple syngeneic murine
models of cancer. Blocking arginase with CB-1158 sig-
nificantly inhibited the growth of CT26, LLC, B16, and
4T1 tumors (Fig. 3a). Confirmation that CB-1158 targets
Arg1 in vivo was assessed with a genetically altered
mouse strain containing a conditional disruption of Arg1
in the myeloid lineage [14, 19, 32]. LLC cells injected
into Argflox/flox; Tie2-Cre+ mice (Fig. 3b, indicated as
ARG1ΔM) grew smaller tumors that were similar in size
to CB-1158-treated Argflox/flox; Tie2-Cre− mice (Fig. 3b,
indicated as ARG1WT), and CB-1158 treatment of Arg-
flox/flox; Tie2-Cre+ animals conferred no further reduction
in tumor growth, consistent with specific on-target in-
hibition of Arg1 by CB-1158 (Fig. 3b). Together, these
results provide evidence that Arg1 activity promotes
tumor growth and that elimination of myeloid cell Arg1
expression or pharmacological blockade of arginase by
CB-1158 limits tumor growth in vivo.
A series of experiments was performed to address the
in vivo mechanism of action of CB-1158. First, we con-
firmed that CB-1158 is not directly cytotoxic to murine
cancer cell lines by assaying the growth of CT26, LLC,
B16, and 4T1 cell lines in the presence of a dose-
titration of CB-1158. No growth inhibition of murine
cancer cell lines was observed in the presence of 1 mM
CB-1158 (Fig. 4a). Next, to test if the mechanism of in
vivo efficacy of CB-1158 is immune cell-mediated, CB-
1158 was administered to LLC tumor-bearing SCID
mice. The efficacy of CB-1158 was abrogated in the
SCID background (Fig. 4b), indicating CB-1158 requires
an intact immune system to inhibit tumor growth. To
confirm the immune cell-mediated mechanism of action
of CB-1158, tumor growth was assessed in mice lacking
immune cell subsets. Depletion of either CD8+ cells or
NK cells in the B16 (Fig. 4c) and CT26 (Fig. 4d) tumor
models blocked the efficacy of CB-1158, indicating that
both CD8+ cells and NK cells are required for the full
anti-tumor effect of CB-1158 in these models. In the






Fig. 2 CB-1158 has favorable pharmacokinetic and pharmacodynamic properties in vivo with no overt signs of toxicity. LLC tumor-bearing mice
(N = 5 per group) were administered a single dose of CB-1158 (a) or 5 twice-daily doses (b) and samples were collected 2 h after the last dose.
CB-1158 and L-arginine in plasma and tumor lysates were measured by LC/MS. c Body weights of mice inoculated with CT26 cells and dosed
with vehicle or CB-1158 twice daily for 23 days. (**** P < 0.0001; *** P < 0.001; ** P < 0.01 vs. vehicle)
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of efficacy, while depletion of CD8+ cells had a smaller
effect (Fig. 4e). Collectively, these results indicate that
the anti-tumor effect of CB-1158 is mediated by the im-
mune system and requires cytotoxic lymphocytes.
To further investigate the immune cell-mediated
mechanism of action of CB-1158, flow cytometry was
performed on tumors from animals treated with vehicle
or CB-1158 and changes in specific immune cell
populations were quantified. In each of the models
where tumor growth was inhibited by CB-1158, we ob-
served statistically significant changes in immune cell
populations indicative of an increase in inflammation in
the TME (Fig. 5). In the CT26 (Fig. 5a) and B16 (Fig. 5b)
models, CB-1158 treatment resulted in an increase in
tumor-infiltrating activated CD8+ CD25+ cytotoxic T
cells compared to vehicle-treated controls. In the LLC
model, CB-1158 treatment caused an increase in CD8+
T cells in the tumor, as well as a decrease in CD68+ mac-
rophages, compared to vehicle-treated controls (Fig. 5c).
In the 4T1 model, where CB-1158 had a modest effect
on tumor growth, we nevertheless observed changes in
immune cell populations consistent with increased in-
flammation in the tumor: an increase in CD3+ T cells,
an increase in NK cells, and a decrease in myeloid cells
in the tumors of CB-1158-treated animals compared to
vehicle-treated controls (Fig. 5d). Consistent with in-
creased inflammation in the tumors of CB-1158-treated
animals compared to vehicle controls, CB-1158 was
linked to increases in transcripts of interferon-
responsive genes (Fig. 5e) and increases in inflammatory
cytokines (Fig. 5f ). Taken together, our data indicate that
the molecular mechanism of tumor growth inhibition by
CB-1158 is immune cell-mediated and results from an
increase in inflammation in the tumor microenviron-
ment that includes an increase in cytotoxic lymphocytes
and a decrease in myeloid cells.
In growing tumors, effective immunity may be blocked
by more than one suppressive mechanism, including ex-
pression of immune checkpoint proteins and depletion
of essential nutrients from the TME [33–35]. We rea-
soned that combining CB-1158 with other immune-
modulating agents might further reduce tumor growth
and tested this idea with four different combinations.
First, CT26 tumor-bearing mice were treated with CB-
1158 in combination with the checkpoint blockade ther-
apy anti-PD-L1. While tumor growth was reduced with
CB-1158 or anti-PD-L1 as monotherapies, tumor growth
inhibition was enhanced by combining the two agents
(Fig. 6a, left). Complete tumor regression was achieved
in three out of ten mice treated with anti-PD-L1 alone,
whereas the combination therapy resulted in six
complete responses (Fig. 6a, center), with 90% survival
at study day 46 for the combination group compared to
30% survival for the anti-PD-L1 single agent group (Fig. 6a,
right). Combination efficacy with checkpoint blockade
therapy was further explored in the orthotopic 4T1 tumor
model, where the addition of CB-1158 to the doublet regi-
men of anti-CTLA-4 and anti-PD-1 resulted in a signifi-
cant reduction in growth of the primary tumor as well
as a decrease in the number of lung metastases (Fig.
6b). Next, we used two different cellular immunother-




Fig. 3 Arginase inhibition reduces tumor growth in vivo. a CB-1158,
dosed at 100 mg/kg twice daily, reduced tumor growth as a single agent
in multiple syngeneic mouse models of cancer (N= 10 per group). b
Mice lacking Arg1 gene expression in the myeloid compartment
(indicated as ARG1ΔM) grow smaller tumors than mice containing
wild-type Arg1 (indicated as ARG1WT), and treatment of ARG1ΔM
mice with CB-1158 does not further reduce tumor growth, indicating
on-target activity of CB-1158 (N = 16 per group). (T test: **** P < 0.0001;
* P < 0.05)
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mice treated with CB-1158 in combination with T cells
specific for the PMEL tumor antigen exhibited signifi-
cantly reduced tumor growth compared to mice treated
with either single agent (Fig. 6c). Of note, the signifi-
cant tumor growth inhibition in mice treated with the
combination of CB-1158 plus T cells is consistent with
the striking survival benefit that was reported for T cell
therapy in mice deleted for myeloid Arg1 [32]. We also
used NK cell therapy in a lung metastasis model. CT26
tumor-bearing mice treated with CB-1158 in combin-
ation with NK cells had significantly fewer lung metas-
tases compared to control groups (Fig. 6d). These
results indicate that CB-1158 may be an attractive com-
bination agent with other immuno therapies.
Some standard-of-care chemotherapeutics have been
observed to modulate the immune infiltrate [36, 37].
While the primary mechanism of action of gemcitabine, a
nucleoside analog, is considered to be inhibition of DNA
synthesis, it has also been observed to reduce MDSCs
[38–40]. Therefore, we reasoned that gemcitabine may
augment the activity of CB-1158. Indeed, CB-1158 treat-
ment in combination with gemcitabine resulted in a sig-
nificant increase in tumor growth inhibition in the CT26,
LLC, and 4T1 tumor models (Fig. 7a). We investigated the
mechanism of action of the combination of CB-1158 and
gemcitabine treatment in the CT26 tumor model by per-
forming flow cytometry on these tumors. Gemcitabine




Fig. 4 CB-1158 requires an intact immune system for efficacy. a CellTiterGlo assays (72 h) were performed on the indicated cell lines with a dose-titration
of CB-1158. b B6.CB17-Prkdc (SCID)/SzJ mice were implanted with LLC cells and CB-1158 was dosed 100 mg/kg twice daily. c-e Tumor growth inhibition
by CB-1158 in the B16 (c), CT26 (d), and LLC (e) models is mediated by CD8+ and NK cells. Tumor-bearing mice were treated with depleting antibodies
and dosed twice-daily with vehicle or 100 mg/kg CB-1158. Tumors from LLC studies were analyzed on study day 13 (CD8+ cell depletion) or study day
14 (NK cell depletion). (**** P< 0.0001; *** P< 0.001; ** P< 0.01)
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myeloid cells in the tumors (Fig. 7b). We note that al-
though gemcitabine can be toxic to immune cells, both
lymphocytes and myeloid cells remained present in gem-
citabine-treated animals with the dose regimen that
was used. Interestingly, NK cells and inflammatory
(M1-type, CD80+) macrophages were significantly
increased, while immunosuppressive (M2-type, CD206
+) macrophages were significantly reduced in tumors
of animals treated with the combination of CB-1158
and gemcitabine, indicating an increase in inflamma-
tion and a decrease in immune suppression in the








Fig. 5 CB-1158-treated animals have increased tumor-infiltrating cytotoxic cells and decreased myeloid cells. a CT26 tumors from animals treated
with CB-1158 had increased CD8+ CD25+ T cells as determined by flow cytometry compared to vehicle-treated animals on study day 14 (N = 10
per group). b In the B16 model, CB-1158 treatment resulted in an increase in CD25+ CD8+ T cells observed on study day 9 (N = 10 per group). c
In the LLC model, CB-1158 treatment resulted in increased tumor infiltrating CD8+ T cells and decreased CD68+ myeloid cells observed on study
day 14 (N = 10 per group). d In the 4T1 model, CB-1158 treatment resulted in increases in both T cells and NK cells and a decrease in myeloid
cells observed on study day 10 (N = 10 per group). e CB-1158 increases T cell and NK cell markers and interferon response genes. mRNA transcripts in
LLC tumors from mice treated with vehicle or 100 mg/kg CB-1158 twice daily were determined by Nanostring (N = 6 per group). f Cytokines and
chemokines in LLC tumors from mice treated with vehicle or 200 mg/kg CB-1158 twice daily were determined by Luminex (N = 5 per group). (T test:
** P < 0.01; * P < 0.05)
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To investigate which tumor types may be more likely
to respond to arginase inhibition, we interrogated hu-
man tumor microarrays by immunohistochemistry for
Arg1 protein expression. The Arg1 antibody was vali-
dated using normal liver tissue as a positive control and
normal tonsil tissue as a negative control (Fig. 8b). We
found an abundance of Arg1+ infiltrating immune cells
in multiple tumor types, with especially high numbers in
tumors of the lung, gastrointestinal tract, and bladder
(Fig. 8a and d). Tumor cells were largely negative for
Arg1 staining with the exception of HCC (Fig. 8c).
Tumor tissue microarrays were also stained by multi-
parameter immunofluorescence for Arg1 and other im-















Fig. 6 CB-1158 combines with immune checkpoint blockade, T cell transfer, or NK cell transfer to inhibit tumor growth. a CB-1158 in combination
with PD-L1 blockade inhibited tumor growth in the CT26 model. Growth curves (left and center) and survival curves (right) are shown. N = 10 per
group. b CB-1158 combined with CTLA-4 and PD-1 blockade to inhibit tumor growth and lung metastases in the 4T1 tumor model. N = 10 per
group. c CB-1158 and adoptive T cell transfer inhibited tumor growth in the B16 model. Non-myeloablative chemotherapy regimen of cyclophosphamide
plus fludarabine (C/F) was administered to all groups, and IL-2 was dosed to groups receiving T cells. On study day 9, Pmel-1 T cells were transferred to
mice in the T cell groups (ACT). N= 10 per group. d CB-1158 and adoptive NK cell transfer reduced lung metastases in the CT26 model. N = 6 control;
N = 7 CB-1158; N = 5 NK cells; N = 5 CB-1158 + NK cells. (T test: **** P < 0.0001; *** P < 0.001; ** P < 0.01; * P < 0.05)
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frequently associated with the granulocytic marker
CD15 than with the macrophage marker CD68 (Fig. 8e),
and in some cases, striking co-localization between Arg1
and CD15 was observed (Fig. 8f ). These data confirm
Arg1 expression in multiple tumor types.
In addition to tumor expression, Arg1 protein and ac-
tivity have been observed in the peripheral blood and
have been reported to be higher in the plasma of some
cancer patients compared to healthy volunteers [25]. To
investigate whether the amount of Arg1 is higher in can-
cer patients than in healthy donors, Arg1 protein was
measured in the plasma of 31 healthy donors and 76
cancer patients across 13 different histologies (see
Methods). Arg1 was significantly higher for cancer pa-
tients compared to the healthy volunteers (Fig. 8g). Per-
ipheral blood L-arginine has also been reported to be
lower in cancer patients [25, 26]. Plasma L-arginine was
measured for 20 healthy volunteers and 26 cancer pa-
tients across 7 different histologies. L-arginine was sig-
nificantly lower for the cancer patients compared to the
healthy individuals (Fig. 8h). These results suggest that
cancer patients may experience immune suppression
that is associated with higher circulating Arg1 and lower
amounts of L-arginine compared to healthy individuals,
a
b
Fig. 7 CB-1158 combines with gemcitabine to inhibit tumor growth. a CB-1158 in combination with gemcitabine treatment in the CT26 model
(left), the LLC model (center), or the 4T1 model (right) inhibited tumor growth. N = 10 per group. b On study day 14, CT26 tumors from animals
treated with CB-1158 and gemcitabine had decreased myeloid cells (upper left), increased NK cells (upper right), decreased suppressive macrophages
(lower left), and increased inflammatory macrophages (lower right) as determined by flow cytometry compared to vehicle-treated animals
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and that inhibiting circulating Arg1 and raising plasma
L-arginine with CB-1158 could confer an immune bene-
fit in the context of cancer.
Discussion
We reasoned that raising arginine levels would be
immune-stimulatory in the context of cancer for the
following reasons: first, cytotoxic lymphocytes require ex-
ogenous arginine for proliferation in response to in vitro
stimulation [10, 11, 28, 29]; second, many cancer patients
are immunosuppressed and have lower plasma arginine
compared to healthy individuals [25, 26]; and lastly, acti-
vated immunosuppressive myeloid cells consume arginine








Fig. 8 Arginase 1 is abundant in multiple types of cancer. a Immunohistochemistry of human tumor tissue microarrays stained with an anti-Arg1
antibody were quantified for Arg1-positive infiltrating granulocytes by digital histopathology. b-d Immunohistochemistry staining for Arg1 in sections of
normal human tissues (N= 33 tissues analyzed) and human tumor tissues (N= 12 tumor histologies analyzed). Representative images are shown. Red
arrows point to arginase-expressing myeloid cells. e Percentage of Arg1-positive cells that co-express the granulocyte marker, CD15, or macrophage
marker, CD68, in tumor tissue microarrays as determined by quantitation of MultiOmyx immunofluorescence. f Immunofluorescent staining (MultiOmyx)
of a tumor section from a patient with head & neck cancer shows numerous Arg1-positive granulocytes. g Plasma Arg1 protein determined by
ELISA from cancer patients (N = 76 from 13 different histologies) and healthy volunteers (N = 31). h Plasma L-arginine determined by LC/
MS from cancer patients (N = 26 from 7 different histologies) and healthy volunteers (N = 20). (**** P < 0.0001 vs. healthy donor)
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cytotoxic lymphocytes in the TME for this amino acid [8,
12]. Thus, raising arginine in cancer patients could be crit-
ical for the immune system to mount an effective anti-
tumor response.
Arginine depletion by myeloid cells is primarily medi-
ated by the enzymes Arg1 and NOS [8]. While there is
conflicting data regarding the role of NOS in inflammation
[32, 41], Arg1 activity in myeloid cells has been shown to
be immunosuppressive and pro-tumorigenic: first, Arg1-
expressing myeloid cells consume arginine from the media
and suppress T cell activity in co-culture, and importantly,
T cell proliferation can be restored either by restoring ar-
ginine to the media or by the addition of an arginase in-
hibitor, showing that arginase activity is necessary for the
observed immune suppression (Fig. 1) [10, 11, 25, 42, 43].
Secondly, genetic ablation of Arg1 in the myeloid compart-
ment of tumor-bearing mice was shown to reduce tumor
growth, indicative of a pro-tumorigenic and immune sup-
pressive role for Arg1 in vivo [13, 14, 19, 32]. Thirdly,
blocking arginase activity pharmacologically with nor-
NOHA [15] or CB-1158 (this report) reduces tumor
growth. The present study additionally demonstrates that
Arg1 inhibition with CB-1158 raises tumor and plasma ar-
ginine and increases inflammation in the TME. Together
these data argue that arginase activity is immunosuppres-
sive and provide validation for arginase as a cancer im-
munotherapy drug target. A second arginase isoform, Arg2
is a constitutively-expressed mitochondrial matrix protein
found at low levels in many tissues and at high levels in
kidney and intestine [21]. Since Arg2 activity also affects
plasma L-arginine levels, Arg2 could also be a regulator of
immune function. In support of this notion, Arg2 has been
reported to promote maternal-fetal immune tolerance [44].
A potential concern with systemic arginase inhibition
is interrupting its function within the urea cycle, an im-
portant pathway in the liver for detoxifying ammonia
generated from the breakdown of amino acids. In spite
of this concern, pharmacological arginase inhibition has
been well-tolerated in several animal studies, including
one study involving a rat model of hypertension in
which nor-NOHA was injected over a period of 10 weeks
[45], as well as multi-day studies of nor-NOHA in mice
[15]. In addition, we have observed that twice-daily oral
dosing of CB-1158 was well-tolerated in mice for at least
40 days. Lack of apparent hepatic toxicity may be ex-
plained by several observations. First, CB-1158 does not
readily enter cells, exhibiting IC50 values for intracellular
arginase in the HepG2 and K562 cell lines that are two
orders of magnitude higher than for soluble arginases in
cell lysates (Tables 1 and 2). Secondly, the subcellular
localization and regulation of urea cycle Arg1 may pro-
tect it from pharmacological inhibition. In hepatocytes,
urea cycle Arg1 is tightly associated at the mitochondria
in a multi-enzyme complex, and studies using semi-
permeabilized cells and radiolabeled substrate have dem-
onstrated that tight channeling of product and substrate
occurs among successive enzymes of the urea cycle: argi-
ninosuccinate synthase, argininosuccinate lyase, and ar-
ginase [46]. Thus, hepatic Arg1 may be less accessible to
CB-1158 compared to cytoplasmic or extracellular argi-
nase in plasma, tumors, and inflamed tissues. When we
tested CB-1158 for the ability to inhibit arginase in in-
tact primary hepatocytes (Table 2), we used media con-
taining ornithine, not arginine, and to our knowledge,
urea generated under these conditions should require a
complete urea cycle. Therefore, this assay may be a
measure of the Arg1 activity that is exclusively associ-
ated with the urea cycle. However we note that the low
potency of CB-1158 on primary hepatocytes could also
be due to the inability of CB-1158 to penetrate the cell
membrane.
Arginine supplementation has been investigated as a
potential therapy for cancer patients and the clinical re-
sults suggest that raising arginine levels may be benefi-
cial. In one study of 18 colorectal cancer patients
undergoing tumor resection, histopathologic analysis of
biopsies revealed that supplementation of arginine prior
to surgery resulted in an increase in CD16+ and CD56+
NK cells infiltrating the tumors [47]. In another study of
96 breast cancer patients, a significant increase in patho-
logical response was observed in patients with small tu-
mors receiving arginine compared to placebo [48].
These data indicate that supplemental arginine may have
an immune-stimulatory and anti-tumor effect in cancer
patients, and suggest that raising systemic arginine by
pharmacological arginase inhibition would be similarly
beneficial. However, major limitations to therapeutic oral
arginine supplementation include severe gastrointestinal
distress and extensive metabolism of arginine by the in-
testinal mucosa [9, 49–51]. CB-1158 treatment has the
potential to both augment and maintain arginine levels
in patients thereby avoiding the gastrointestinal distress
and arginine oscillations inherent to dietary arginine
supplementation.
Antibodies to T cell checkpoint proteins CTLA-4, PD-
1, and PD-L1 have resulted in durable clinical responses
for some cancer patients, but many patients do not re-
spond [52, 53], suggesting that overcoming additional
immunosuppressive mechanisms will be necessary to re-
activate anti-tumor immunity in resistant patients. The
cellular and molecular basis of resistance to checkpoint
blockade is an area of intense investigation. Biomarker
studies examining responsive and resistant patients point
to a suppressive TME as one possibility to explain resist-
ance. Patients with a higher baseline level of T cells infil-
trating the tumor (T cell-inflamed tumors) compared to
non-responsive tumors (cold tumors) were more likely
to respond to anti-CTLA-4 or anti-PD-1 therapies [54],
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and patients resistant to anti-PD-1 therapy had higher
baseline levels of tumor-infiltrating MDSCs compared to
responders [55]. Furthermore, pre-clinical studies have
shown that the depletion of essential extracellular me-
tabolites in the TME, such as glucose and amino acids,
can block T cell effector function [56, 57]. Together,
these results suggest that immunosuppressive myeloid
cells and depletion of essential metabolites may give rise
to cold tumors that are resistant to checkpoint blockade
and therefore targeting these myeloid cells and meta-
bolic regulatory pathways, in combination with check-
point antibodies, could restore inflammation and
increase patient response rates. In support of this hy-
pothesis, epacadostat, which inhibits the enzyme IDO-1
and prevents depletion of the essential amino acid tryp-
tophan from the TME, is exhibiting striking results in
combination with anti-PD-1 therapy in patients with
melanoma, lung cancer, RCC, or head and neck carcin-
oma [58–62], arguing that targeting T cell checkpoints
and immunosuppression by the TME is an efficacious
combination.
Conclusions
In this report, we have shown that inhibition of arginase
with CB-1158, a potent, selective, and orally-bioavailable
small molecule, reverses suppression of T cell prolifera-
tion by blocking arginine depletion. CB-1158 reduced
tumor growth in mouse models of cancer by increasing
inflammation in the TME, confirming an immune-
modulatory mechanism of action in vivo. In addition,
CB-1158 treatment of tumor-bearing mice enhanced the
efficacy of checkpoint blockade, adoptive T cell therapy,
adoptive NK cell therapy, and gemcitabine treatment. A
survey of human tumor microarrays and cancer patient
plasma confirmed Arg1 expression is elevated in human
cancer. These findings provide strong rationale for the
clinical development of CB-1158 as an anti-cancer thera-
peutic agent. A Phase 1 study (NCT02903914) has been
initiated to test the anti-tumor activity of CB-1158, as a
monotherapy and in combination with anti-PD-1, in
order to add to the armamentarium of agents that acti-
vate the immune system to fight cancer.
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